Journal Title：Psychopharmacology

Official Journal of the European Behavioural Pharmacology Society (EBPS)

Psychopharmacology is an international journal that covers the broad topic of elucidating mechanisms by which drugs affect behavior. The scope of the journal encompasses the following fields:

Human Psychopharmacology: Experimental

This section includes manuscripts describing the effects of drugs on mood, behavior, cognition and physiology in humans. The journal encourages submissions that involve brain imaging, genetics, neuroendocrinology, and developmental topics. Usually manuscripts in this section describe studies conducted under controlled conditions, but occasionally descriptive or observational studies are also considered.

Human Psychopharmacology: Clinical and Translational

This section comprises studies addressing the broad intersection of drugs and psychiatric illness. This includes not only clinical trials and studies of drug usage and metabolism, drug surveillance, and pharmacoepidemiology, but also work utilizing the entire range of clinically relevant methodologies, including neuroimaging, pharmacogenetics, cognitive science, biomarkers, and others. Work directed toward the translation of preclinical to clinical knowledge is especially encouraged. The key feature of submissions to this section is that they involve a focus on clinical aspects.

Preclinical psychopharmacology: Behavioral and Neural

This section considers reports on the effects of compounds with defined chemical structures on any aspect of behavior, in particular when correlated with neurochemical effects, in species other than humans. Manuscripts containing neuroscientific techniques in combination with behavior are welcome. We encourage reports of studies that provide insight into the mechanisms of drug action, at the behavioral and molecular levels.

Preclinical Psychopharmacology: Translational

This section considers manuscripts that enhance the confidence in a central mechanism that could be of therapeutic value for psychiatric or neurological patients, using disease-relevant preclinical models and tests, or that report on preclinical manipulations and challenges that have the potential to be translated to the clinic. Studies aiming at the refinement of preclinical models based upon clinical findings (back-translation) will also be considered. The journal particularly encourages submissions that integrate measures of target tissue exposure, activity on the molecular target and/or modulation of the targeted biochemical pathways.

Preclinical Psychopharmacology: Molecular, Genetic and Epigenetic

This section focuses on the molecular and cellular actions of neuropharmacological agents / drugs, and the identification / validation of drug targets affecting the CNS in health and disease. We particularly encourage studies that provide insight into the mechanisms of drug action at the molecular level. Manuscripts containing evidence for genetic or epigenetic effects on neurochemistry or behavior are welcome.

歐洲行為藥理學(xué)會(huì) (EBPS) 官方期刊

《精神藥理學(xué)》是一本國(guó)際期刊，涵蓋闡明藥物影響行為的機(jī)制這一廣泛主題。該期刊的范圍涵蓋以下領(lǐng)域：

人類精神藥理學(xué)：實(shí)驗(yàn)

本部分包括描述藥物對(duì)人類情緒、行為、認(rèn)知和生理影響的稿件。該期刊鼓勵(lì)提交涉及腦成像、遺傳學(xué)、神經(jīng)內(nèi)分泌學(xué)和發(fā)育主題的稿件。本部分中的稿件通常描述在受控條件下進(jìn)行的研究，但偶爾也會(huì)考慮描述性或觀察性研究。

人類精神藥理學(xué)：臨床和轉(zhuǎn)化

本部分包括涉及藥物和精神疾病廣泛交集的研究。這不僅包括臨床試驗(yàn)和藥物使用和代謝、藥物監(jiān)測(cè)和藥物流行病學(xué)的研究，還包括利用各種臨床相關(guān)方法的工作，包括神經(jīng)影像學(xué)、藥物遺傳學(xué)、認(rèn)知科學(xué)、生物標(biāo)志物等。特別鼓勵(lì)將臨床前知識(shí)轉(zhuǎn)化為臨床知識(shí)的工作。提交到本節(jié)的主要特點(diǎn)是它們涉及臨床方面。

臨床前精神藥理學(xué)：行為和神經(jīng)

本節(jié)考慮具有明確化學(xué)結(jié)構(gòu)的化合物對(duì)人類以外物種的行為任何方面的影響的報(bào)告，特別是與神經(jīng)化學(xué)效應(yīng)相關(guān)時(shí)。歡迎包含與行為相結(jié)合的神經(jīng)科學(xué)技術(shù)的稿件。我們鼓勵(lì)報(bào)告在行為和分子水平上深入了解藥物作用機(jī)制的研究。

臨床前精神藥理學(xué)：轉(zhuǎn)化

本部分考慮使用與疾病相關(guān)的臨床前模型和測(cè)試來(lái)增強(qiáng)對(duì)可能對(duì)精神病或神經(jīng)病患者具有治療價(jià)值的核心機(jī)制的信心的手稿，或報(bào)告可能轉(zhuǎn)化為臨床的臨床前操作和挑戰(zhàn)的手稿。旨在根據(jù)臨床發(fā)現(xiàn)（反向翻譯）改進(jìn)臨床前模型的研究也將受到考慮。該期刊特別鼓勵(lì)提交整合靶組織暴露測(cè)量、分子靶標(biāo)活性和/或靶向生化途徑調(diào)節(jié)的投稿。

臨床前精神藥理學(xué)：分子、遺傳和表觀遺傳

本部分重點(diǎn)介紹神經(jīng)藥理學(xué)藥劑/藥物的分子和細(xì)胞作用，以及影響健康和疾病中樞神經(jīng)系統(tǒng)的藥物靶標(biāo)的識(shí)別/驗(yàn)證。我們特別鼓勵(lì)在分子水平上深入了解藥物作用機(jī)制的研究。歡迎包含遺傳或表觀遺傳對(duì)神經(jīng)化學(xué)或行為影響的證據(jù)的稿件。

Psychopharmacology創(chuàng)刊于1959年，由Springer Berlin Heidelberg出版商出版，收稿方向涵蓋醫(yī)學(xué) - 精神病學(xué)全領(lǐng)域，此刊是中等級(jí)別的SCI期刊，所以過(guò)審相對(duì)來(lái)講不是特別難，但是該刊專業(yè)認(rèn)可度不錯(cuò)，仍然是一本值得選擇的SCI期刊 。平均審稿速度 較快,2-4周 ，影響因子指數(shù)3.5，該期刊近期沒(méi)有被列入國(guó)際期刊預(yù)警名單，廣大學(xué)者值得一試。